Epidemiology

Epidemiology

Translational Research in Clinical Oncology
October, 2016

Neil Caporaso, MD

Chief, Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute

caporaso@nih.gov

A Population Perspective on Cancer


- foundations (introductory concepts)
 - tools epidemiologists use
 - accomplishments
 - challenges
 - •futures

Population Perspective

A Population Perspective on Cancer

- foundations (introductory concepts)
- tools epidemiologists use
- accomplishments
- challenges
- futures

NIH epidemiology



National Cancer Institute

We are INTRAMURAL ~ 85% \$\$ are extramural

Division of Cancer Epidemiology and Genetics

Genetic Epidemiology Branch

Cancer ETIOLOGY

Other Branches focus on Nutrition, Hormones, Infection, Occupation, Statistics, Radiation

NCI DCEG



NCI's Division of Cancer Epidemiology and Genetics





Division of Cancer Epidemiology and Genetics (DCEG)

- Identify the environmental and genetic causes of cancer in the population
- High quality, high impact, value-added research
- National and international in scope
- Scientific partnerships in molecular epidemiology across NCI and beyond

Major public health advances

Major public health advances

Regulatory changes

- Drinking water
- Gasoline (less benzene)
- Workplace safety (diesel)
- Safer farming

Clinical practice

- Cancer susceptibility syndromes
- Second cancers among cancer survivors

Preventive interventions

- Safer CT scans
- Risk-reducing surgeries for individuals at high-risk
- Benefits of healthy weight and physical activity
- Efficacy of human papillomavirus vaccine for cervical cancer
- Eliminating indoor pollution

Collaborations



DCEG



National Cancer Institute

at the National Institutes of Health I www.cancer.gov

Division of Cancer Epidemiology & Genetics

Discovering the causes of cancer and the means of prevention

Contact Us | Staff Intranet | Sitemap

DCEG Home

About DCEG

Our Research

Fellowships & Training

Tools & Resources

News & Events

Publications



Newly Tenured: Hormuzd Katki

Dr. Hormuzd Katki is now a senior investigator in the Biostatistics Branch His research on risk stratification has led to the development of guidelines and risk-benefit models for cancer screening. He is particularly interested in the principle of "equal management of people at equal risk of cancer."

Learn more about Dr. Katki

Fellowships

DCEG offers a range of fellowships and research training opportunities in our research Branches and with specific investigators.

Learn about our training programs



Complexity of NHL **Subtypes**



Newly Tenured: Hormuzd Katki



Physical Activity, Sedentary Behavior, and Cancer

The Division of Cancer Epidemiology and Genetics (DCEG) is a research program of the National Cancer Institute (NCI), one of the National Institutes of Health (NIH). The Division is the world's most comprehensive cancer epidemiology research group. Its renowned epidemiologists, geneticists, and biostatisticians conduct population and multidisciplinary research to discover the genetic and environmental determinants of cancer and new approaches to cancer prevention. The Division's research impacts public health policy in the United States and around the world.

Scientific Position Openings

Deputy Director

DCEG is recruiting an accomplished, senior scientist to serve as Deputy Director in the Office of the Director. DCEG. Learn more about this opportunity.

Postdoctoral Fellowship

The Radiation Epidemiology Branch is recruiting a postdoctoral fellow to conduct research on health effects

Cancer risk

Cancer risk assessment tools

Breast Cancer Risk Assessment Tool

An interactive tool to help estimate a woman's risk of developing breast cancer

Melanoma Risk Assessment Tool

An interactive tool to help estimate a person's risk of developing invasive melanoma



Colorectal Cancer Risk Assessment Tool

An interactive tool to help estimate a person's risk of developing colorectal cancer



Epidemiology

- Epidemiology = health and disease in human populations
- = epi (upon) + demos (the people) + logia (talk about)
- An OBSERVATIONAL science (like astronomy, evolutionary biology)
 - Contrast with experimental
 - Investigator does NOT get to pick who is exposed or unexposed
 - Free-living people make choices about participating...possible BIAS
 - Contrast with Clinical Research

Observational vs. Experimental

Observational vs. Experimental

Epidemiologists are ethically prohibited from doing experiments on people

So, we observe large populations and see how their outcomes relate to what people do (i.e., smoke, drink, eat, etc.)

This weakness of the 'observational' argument were exploited by tobacco companies to deny evidence linking cigarettes and cancer.....

Goals of Epidemiology

- 1. Identify the causes of cancer
- 2. Quantify risks/identify risk groups
 - 3. Understand mechanisms
 - 4. Public health and health services
 - 5. Identify syndromes

Epidemiologists emphasize prevention

Rationale:

Effective (think polio, smallpox, smoking cessation, clean water, HPV...)

Cheaper (compared to late stage interventions)

Public health orientation

Eliminate disease at the source

Downsides

Requires time to demonstrate effectiveness

Less dramatic than treatment

Can't see disease you have prevented

Lives saved appear in statistics- not grateful patients

Less positive political impact (= funding)

Political opposition from powerful groups (Tobacco, Soft Drink Companies, Polluters,

etc.)

No Nobel Prizes

Primary = directed to susceptibility stage

Example: Needle exchange to prevent AIDS, HPV vaccine

Secondary = directed to subclinical stage

Example: Screen for cervical cancer with Pap Smear

Tertiary = directed to clinical stage

Example: Treat diabetic retinopathy to prevent blindness

Epidemiologists worry about bias

Bias= systematic deviation from truth
Epidemiologists fret about PARTICIPATION RATES

if too low.....

study subjects not REPRESENTATIVE
of the target populations
results not be GENERALIZABLE
to the general population

Selection Bias = subjects in the study are 'selected' and therefore nonrepresentative

Participation rate

Pilot studies: participation rate

30%

Phone Survey 49%

- Invitation letter
- Follow-up by phone
- In hospital
- Advertisements
- Cash award
- Physicians' letter
- Home/hospital

73%

- New interviewers
- Physicians' call
- Gas coupon
- TV ads
- New invitation letter
- Mayor's letter
- Toll-free phone line

Total number of subjects in pilot investigations: 156 Cases - 212 Controls



Clinical data: 99%

Questionnaires: 87%

Biospecimens: 97%

Controls for epidemiologists

Epidemiologists worry about controls

Population controls

Expensive

Most representative (section bias still possible)

Calculate ABSOLUTE risks (contract with RELATIVE risks)

Increasingly difficult- RDD problematic!

Defined in time and space

Inclusion and exclusion criteria

High response rate!

'Convenience' controls are the least desirable

Biased by differences in:

Age, risk factors, ethnicity, education, participation rate, access to care, SES....

Epidemiologist as consultant

Questions the consulting epidemiologist will ask: Your study design is...? Your controls came from....? Did you collect key covariate data? Did you consider bias, confounding? What was the original hypothesis? (data dredging) Have you done power calculations? How did you validate your marker? Epidemiologist is helpful when a question involves the population (as opposed to an individual, organ, cell, etc.)

Can you explain

The most common question epidemiologists get!

Can you explain why.....

My grandmother smoked all her life. her exercise was the TV remote, she never used a seat belt, she ate bacon and buttered toast for breakfast... she drank shots on her 90th birthday

she outlived all her doctors.....

The race is not to the swift or the battle to the strong, nor does food come to the wise or wealth to the brilliant or favor to the learned; but time and chance happen to them all. (Ecclesiastes)

Deterministic vs. Probabilistic


Population Perspective

A Population Perspective on Cancer

- foundations (introductory concepts)
- tools epidemiologists use
- accomplishments
- challenges
- futures

Cancer Maps

MAPS 1



Geographic Information Systems

GIS

Geographic patterns of disease and exposure via satellite Examples, used to estimate nitrate, pesticide levels (see, Ward et al., 2000)

National Cancer Institute

U.S. National Institutes of Health | www.cancer.gov

Home | Contact Us | GISSIG



GIS

Geographic Information Systems

Search: SEARCH TERN (

- Introduction to GIS at NCI
- Geographicbased Research
 Applications at NCI

Introduction to GIS at NCI

Geospatial tools are used at NCI for a variety of applications, including:

- the identification and display of the geographic patterns of cancer incidence and mortality rates in the US and their change over time.
- · the creation of complex databases for the study of cancer screening, diagnosis and survival at the community level,
- environmental exposure assessment through satellite imagery,
- spatial statistical models to estimate cancer incidence, prevalence and survival for every US state,
- · communication of local cancer information to the public and public health professionals through interactive web-based tools,
- the identification of health disparities at the local level through the comparison of cancer outcomes across demographic subgroups, and
- development of new methods of displaying geospatial data for clear communication to the public and for examination of complex multivariate data by researchers.

SEER

Surveillance, Epidemiology, and End Results (SEER) Program 26% of US population incidence and survival, patient demographics, primary tumor site, tumor morphology and stage at diagnosis, first course of treatment, and follow-up for vital status comprehensive source of population-based information

SEER



National Cancer Institute



Surveillance Epidemiology and End Results

providing information on cancer statistics to help reduce the burden of this disease on the U.S. population

Home

Cancer Statistics | Accessing Datasets & Tools

Publications

Welcome to the Surveillance, Epidemiologγ and End Results (SEER) Program, a premier source for cancer statistics in the United States. SEER collects information on incidence, survival, and prevalence from specific geographic areas representing 26 percent of the US population and compiles reports on all of these plus cancer mortality for the entire US. This site is intended for anyone interested in US cancer statistics or cancer surveillance methods.

You can use the tabs to find summarized statistics under Cancer Statistics; instructions for accessing and downloading the data and the software to analyze it under Accessing Datasets <u>& Tools;</u> reports, monographs and the SEER Bibliographγ under <u>Publications;</u> and data collection manuals, training, and resources under Information for Cancer Registrars.

- SEER Program Overview
- SEER Registries
- Research Activities
- Quality Improvement



Cancer Stat Fact Sheets

Get printouts of most recent statistics for each type of cancer.


Select a cancer type from the list:

-Choose a Cancer Site-






Cancer Incidence Rates Cancer Incidence Rates*, All Sites Combined, All Races, 1975-2000



^{*}Age-adjusted to the 2000 US standard population.
Source: Surveillance, Epidemiology, and End Results Program, 1973-1999, Division of Cancer Control and Population Sciences, National Cancer Institute, 2003.

Cancer Rates for Men

Cancer Incidence Rates* for Men, US, 1975-2000




*Age-adjusted to the 2000 US standard population.

Source: Surveillance, Epidemiology, and End Results Program, 1975-2000, Division of Cancer Control and Population Sciences, National Cancer Institute, 2003.

Cancer by sex and race

Cancer Incidence Rates* by Sex and Race, All Sites, 1975-2000


Rate Per 100,000



'Age-adjusted to the 2000 US standard population.
Source: Surveillance, Epidemiology, and End Results Program, 1975-2000, Division of Cancer Control and Population Sciences, National Cancer Institute, 2003.

Cancer and Children

Cancer Incidence & Death Rates* in Children 0-14 Years, 1975-2000



^{*}Age-adjusted to the 2000 Standard population.

Source: Surveillance, Epidemiology, and End Results Program, 1975-2000, Division of Cancer Control and Population Sciences, National Cancer Institute, 2003.

Childhood Cancers

Childhood Cancers (< 14 ys)

- Incidence 8,600 new cases/yr 12,400 (0 – 19 ys)
- Mortality

 1,500 deaths/yr
 2,300 (0 − 19 ys)
 rates ↓ 50% since 1973



Etiology -- poorly understood

How do you prove a cause?


(CLASSICAL)

- 1. It should confer high risk
 - 2. It should be consistent
 - 3. Dose response
 - 4. Cause occurs first!
- 5. Biology makes sense How do you prove a cause?


How do you prove a cause? (TODAY)

- 1. Mendelian Randomization
 - 2. Molecular Epidemiology
 - 3. Mediation analysis


Lung Cancer and smoking




Lung cancer




Lung cancer



Lung cancer



Lung cancer risks



A Population Perspective on Cancer

- foundations (introductory concepts)
 - tools epidemiologists use
 - accomplishments
 - challenges
 - •futures

Coffee and mortality

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Association of Coffee Drinking with Total and Cause-Specific Mortality

Neal D. Freedman, Ph.D., Yikyung Park, Sc.D., Christian C. Abnet, Ph.D., Albert R. Hollenbeck, Ph.D., and Rashmi Sinha, Ph.D.

ABSTRACT

BACKGROUND

National Cancer Institute

Coffee is one of the most widely consumed beverages, but the association between and the risk of death remains unclear.

Conference Training Conference Bay Have Lower Risk of Death Part of Deat

72 media calls

From the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD (N.D.F., Y.P., C.C.A., R.S.); and AARP, Washington, DC (A.R.H.). Address reprint requests to Dr. Freedman at the Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, 6120 Executive Blvd., EPS/320, MSC 7232, Rockville, MD 20852, or at freedmanne@mail.nih.gov.

Smoking and bladder cancer

ORIGINAL CONTRIBUTION

Association Between Smoking and Risk of Bladder Cancer Among Men and Women

Neal D. Freedman, PhD, MPH
Debra T. Silverman, ScD, ScM
Albert R. Hollenbeck, PhD
Arthur Schatzkin, MD, DrPH†
Christian C. Abnet, PhD, MPH

ORE THAN 350 000 INDIviduals are diagnosed with incident bladder cancer per year worldwide, including more than 70 000 per year in the United States. In data from Surveillance, Epidemiology, and End Results Program, incidence rates in white individuals aged 50 years or more have remained stable during the past 30 years (1976-2006), from 123.8 per **Context** Previous studies indicate that the population attributable risk (PAR) of bladder cancer for tobacco smoking is 50% to 65% in men and 20% to 30% in women and that current cigarette smoking triples bladder cancer risk relative to never smoking. During the last 30 years, incidence rates have remained stable in the United States in men (123.8 per 100 000 person-years to 142.2 per 100 000 person-years) and women (32.5 per 100 000 person-years to 33.2 per 100 000 person-years); however, changing smoking prevalence and cigarette composition warrant revisiting risk estimates for smoking and bladder cancer.

Objective To evaluate the association between tobacco smoking and bladder cancer.

Design, Setting, and Participants Men (n=281 394) and women (n=186 134) of the National Institutes of Health-AARP (NIH-AARP) Diet and Health Study cohort completed a lifestyle questionnaire and were followed up between October 25, 1995, and December 31, 2006. Previous prospective cohort studies of smoking and incident bladder cancer were identified by systematic review and relative risks were estimated from fixed-effects models with heterogeneity assessed by the I^2 statistic.

Main Outcome Measures Hazard ratios (HRs), PARs, and number needed to harm (NNH).

Results During 4518941 person-years of follow-up, incident bladder cancer oc-

Crisis communications over the decades

- Silicone breast implants
- Chernobyl accident
- Oral cancer and mouthwash (alcohol)
- Abortion and breast cancer
- Cell phones and brain tumors
- Fukushima disaster

Accomplishments (highly selected)

- •Identification of the general and specific causes of cancer
- •Role as advocates of public health/ prevention
- •Identification of tobacco as causal factor for lung cancer
- •Role of secondary tobacco smoke
- •Molecular Epidemiology

What are the general risk factors for cancer?

Increasing age
Environmental factors
Genetic factors
Combinations of the above!

Causes of death Causes of Cancer Deaths



^{*} Environmental pollution, Infectious agents, Lifestyle, Alcohol use, Occupational factors, Medicine, Radiation, Genetic susceptibility, other & unknown causes

Most Cancer is due to the Environment

Dramatic differences in cancer rates by geography and over time are only compatible with extrinsic environmental causes

Established by a vast body of descriptive, ecological, and analytical epidemiology

International Variation in Cancer Rates

Type of cancer	H/L highest lowest		
Melanoma	155	Australia	Japan
Nasopharynx	100	Hong Kong	UK
Prostate	70	US (Blacks)	China
Liver	50	China	Canada
Cervix	28	Brazil	Israel
Stomach	22	Japan	Kuwait
Lung	19	US (Blacks)	India
Colon	19	US (Whites)	India
Bladder	16	Switzerland	India
Pancreas	11	US (Blacks)	India
Ovary	8	Maori (NZ)	Kuwait
Breast		7 Hawaii Israel	
Leukemia		5 Canada India	

Lung cancer mortality

Lung cancer mortality rate in Xuan Wei is among the highest in China



County-specific female lung cancer mortality rates (per 100,000, 1973-75)


Air pollution



Indoor Air Pollution in China












Air pollution



Skull



Skull With Cigarette

van Gogh


JAMA, cover, 1966, Feb 28, 1986

Tobacco and public health

major cause of preventable morbidity & mortality 1/5 US deaths (450,000 USA, 3M world/y) 10 million tobacco deaths/yr (2030, WHO) 30% of all cancer, 8 sites, all difficult to treat tobacco related disease costs Medicare/ Medicaid > \$10B/yr each In spite of widespread knowledge of the health consequences of smoking - rates in US adults, 15% (2014) - individual smoking cessation very difficult

Tobacco consumption

Per-Capita Consumption of Different Forms of Tobacco in The U.S. 1880-2003



Environmental Tobacco Smoke (ETS)

never-smoking women spouses of smokers at higher risk then spouses of non-smokers (*Hirayama, Trichopoulos, 1981*) NRC Report

Nonsmoking spouses have 30% increased risk 25% of cases in non-smokers due to smoking

~ 3000 deaths per year

ETS classified as Class A human carcinogen

Surgeon General Report (1986) and EPA Review (1992)

Metanalyses conclude that ETS (both workplace and at home)

is a significant risk factor, e.g. Law, 1997

Summary:

Evidence implicating ETS suggests dose-response extends to lowest exposures, i.e. no threshold

What are alcohol-associated cancers? Oral **Pharynx Esophagus** Larynx Liver


Leukemia (AML, but not CLL*) Breast Lung Thyroid Head and neck cancer

Ionizing Radiation and Cancer

Type of XRT	Study	Cancer
	Implicated	
A-Bomb	Japan	Breast, Leuk,
	Gastric, Thy	
A-Bomb	Marshall Island	Thyroid
Medical	Breast/Mastitis	Breast
Medical	Hemangioma	Breast, Thyroid
Medical	Hodgkin's	Breast, lung,
	Thyroid	
Medical	TB-Flouroscopy	Breast
Radionuclides	Thorotrast	Leukemia, Liver
	(Th-232)	
Radionuclides	Spondylytis	Bones (Ra-224)
Occupation	Radium Dial pair	nters Bone
Occupation	Rad Technicians	Leukemia
Occupation	Chernobyl Clea	anup ?
Environmental	Indoor radon	Lung


Cancer risk

Cancer Risks Following Chernobyl Accident



- I-131 dose-response for thyroid cancer significantly elevated (ERR=2.2/Gy) in residents <18 yrs
- Elevated risks persisted for 2 decades; no decrease to date

Brenner...Hatch...Lubin...Bouville...Ron. Environ Health Perspect 2011



Dose-response similar for chronic lymphocytic leukemia (CLL) (ERR=4.1/Gy) and for non-CLL leukemia (ERR=2.7/Gy) in clean-up workers

Romanenko...Hatch...Bouville...Ron et al. Radiat Res 2008

Skin cancer

Non-lonizing Radiation (UV/sun)

- 1 Basal cell
- 2 Squamous cell
- 3 Melanoma,

Tanning beds!

Skin damage



Infections and Cancer

Infections and Cancer

Human papillomavirus	Cervical cancer	
	Vulvar/vaginal cancer	
	Anal cancer	
	Penile cancer	
	Oropharyngeal cancer	
Hepatitis B & C virus	Hepatocellular	
	Non-Hodgkin's lymphoma	
Helicobacter pylori	Gastric cancer	
Liver flukes	Cholangiocarcinoma	

Newer infections

Newer infectious hypotheses

VIRUS	Human Cancer	(hypothesized

hepatocellular cancer

NHL

NPC

Hodgkin's lymphoma

leiomyosarcoma

Kaposi's sarcoma

Vulvo-vaginal cancer

Anal cancer

Penile cancer

Oropharyngeal cancer

Merkel cell virus/ CLL?

NHL

HCV

EBV

KSHV (HHV8) HPV-16, -18, -33, -39

Polyomavirus HIV

Oropharynx cancer

Pre-diagnostic HPV16 Antibodies Strongly Associated with Oropharynx Cancers - Nested Case-Control Study Within EPIC Cohort


HPV type and antibody	Cases N=135 N (%)	Controls N=1599 N (%) Specific	OR (95%CI) Strong
HPV16 E6	47 (34.8%)	(0.6%)	274 (110 to 681)
HPV16 E7	27 (20.0%)	178 (11.3%)	2.4 (1.5 to 3.9)
HPV16 E1	22 (16.3%)	63 (3.9%)	5.7 (3.2 to 10)
HPV16 E2	33 (24.4%)	72 (4.5%)	9.5 (5.7 to 16)
HPV16 L1	56 (41.5%)	329 (20.6%)	3.1 (2.1 to 4.5)

Kreimer et al, Manuscript under review

Colon cancer

Genomic analysis identifies association of *Fusobacterium* with colorectal carcinoma

Aleksandar D. Kostic, ^{1,2} Dirk Gevers, ¹ Chandra Sekhar Pedamallu, ^{1,3} Monia Michaud, ⁴ Fujiko Duke, ^{1,3} Ashlee M. Earl, ¹ Akinyemi I. Ojesina, ^{1,3} Joonil Jung, ¹ Adam J. Bass, ¹ Josep Tabernero, ⁵ José Baselga, ⁵ Chen Liu, ⁶ Ramesh A. Shivdasani, ³ Shuji Ogino, ², ⁹ Bruce W. Birren, ¹ Curtis Huttenhower, ^{1,8} Wendy S. Garrett, ^{1,3,4} and Matthew Meyerson ^{1,2,3,9}



Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma

Mauro Castellarin,^{1,2,6} René L. Warren,^{1,6} J. Douglas Freeman,¹ Lisa Dreolini,¹ Martin Krzywinski,¹ Jaclyn Strauss,³ Rebecca Barnes,⁴ Peter Watson,⁴ Emma Allen-Vercoe,³ Richard A. Moore,^{1,5} and Robert A. Holt^{1,2,7}

¹BC Cancer Agency, Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 1L3, Canada; ²Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada; ³University of Guelph, Guelph, Ontario N1G 2W1, Canada; ⁴BC Cancer Agency, Deeley Research Centre, Victoria, British Columbia V8R 6V5, Canada; ⁵Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada

Occupational exposures

OCCUPATIONAL EXPOSURES -- HUMAN CARCINOGENS

EXPOSURE

4-Aminobiphenyl

Arsenic

Asbestos

Benzene

Benzidine

beta-Naphthylamine

Coal tars and pitches

Mineral oils

Mustard gas

Radon

Soot, tars, and oils (polycyclic hydrocarbons)

Vinyl chloride

Wood dusts (furniture)

SITE OF CANCER

Bladder

Lung, skin

Lung, pleura,

peritoneum

Leukemia

Bladder

Bladder

Lung, skin

Skin

Pharynx, lung

Lung

Lung, skin

Liver

Nasal sinuses

Diesel exhaust

Diesel Exhaust in Miners Study (OEEB, BB, NIOSH)

- Significant exposure-response based on quantitative historical exposure data, adjusting for smoking and other confounders (Silverman et al, JNCI, 2012)
- Played an influential role in IARC's reclassification of diesel exhaust as a Group 1 carcinogen



A Population Perspective on Cancer

- •foundations (introductory concepts)
 - •tools epidemiologists use
 - accomplishments
 - •challenges
 - •futures

gaps on the ENVIRONMENT side

- •For many cancers, risk factors are unknown?
- •For cancers where general 'cause', is understood, individual susceptibility is poorly understood
 - •How G and E work in concert is poorly understood.
- •Some potential causes are poorly studied.....

Chronic Lymphocytic Leukemia

- Most common leukemia of Western world.
- 30% of adult leukemia in USA
- Less frequent in Asia and Latin America.
- Male to female ratio is 2:1.
- Median age at diagnosis is 65-70 years.
- No extrinsic environmental causes known
- Family history is the most important risk factor

DIETARY RISK FACTORS What are some dietary risk factors?


High calories Uterine

Low fiber Colon

Micronutrients Lung (?)

Diet contaminants Liver

Diet and lung cancer




Diet and lung cancer

Many questions.....

- 1.Failure of 'nutrient' based interventions (ATBC and beta carotene)
- 2. Role of 'processed' vs. 'traditional' food
- 3. Food?/nutrients? How to best aggregate consumed items to identify risk or protection?
- 4. Meat and vegetable consumption

Diet and lung cancer

Higher frequency of fresh red and processed meat intake **increased** lung cancer risks



gaps on the GENETIC side

New technologies have accelerated gene discovery but...

- •Genes associated with common cancers confer minimal risk
- and explain only a small portion of the variation
 - •and do not help much with risk models
 - How G and E work in concert is poorly understood
 - •Many cancer families- genes remain obscure

All Cancer is due to the Genetic changes

All cancer cells exhibit changes in their

DNA that are passed on and maintain

the 'malignant phenotype'

GETTING ORIENTED

- Germline or Somatic
 (inherited or in the tumor)
- 2. Family or Population (rare or common)
- 3. Candidate or Agnostic (candidate gene study or GWAS)

Family history

Lung Cancer Risk and Family History


Family member	Controls	Case	OR (95% CI)*
Mother	2044 19	1817 30	2.11 (1.11-4.41)
Father	1890 108	1678 139	1.37 (1.01-1.87)
Sibling	1356 93	1152 140	1.53 (1.10-2.12
Any family member	1430 213	1142 294	1.57 (1.25-1.98)

⁻ Adjusted for 5 year age-interval, sex, residence (5 areas), education (5 categories), personal smoking status (packs/day, duration in years, and years since the last cigarette)

⁻ Data on family history available on 2116 controls and 1946 cases Squamous (32%), Adenocarcinoma (51%), 195 (12%), large (4.5%)

Rare Genes

To look for rare genes you need families......



High risk kindreds like this likely harbor rare genes that confer high risk- if we knew what were they would be clinically important....

Cloned familiar tumor


DOMOD WODDOWALLD

Cloned Familial Tumor Suppressor Genes

Retinoblastoma	RB1	13q14	1986
Wilms' tumor	WT1	11p13	1990
Li-Fraumeni syndrome	p53	17p13	1990
Neurofibromatosis 1	NF1	17q11	1990
Neurofibromatosis 2	NF2	22q12	1993
von Hippel-Lindau	VHL	3p25	1993
Familial melanoma 1	p16	9p21	1994
Familial breast 1	BRCA1	17q21	1994
Familial breast 2	BRCA2	13q12	1995
Basal cell nevus	PTC	9q22	1996

GWAS etiology hits

Published Cancer GWAS Etiology Hits: 8.10.12



Lung cancer challenge

The lung cancer challenge....

- 1- Drives overall cancer mortality in the US and worldwide
- 2- Treatment and screening pose challenges
- 3- Lung cancer is paradigm for genetics of complex disease
- 4- Clearest example of environment and gene in cancer
- 5- The clearest example of a genetically influenced behavior associated with the leading public health problem in the world

2009 Estimated US Cancer Deaths*					
Lung & bronchus	30%	Men 292,540	Women 269,800	26%	Lung & bronchus
Prostate	9%	292,540	209,800	15%	Breast
Colon & rectum	9%			9%	Colon & rectum
Pancreas	6%			6%	Pancreas
Leukemia	4%			5%	Ovary
Liver & intrahepatic bile duct	4%			4%	Non-Hodgkin Iymphoma
Esophagus	4%			3%	Leukemia
Urinary bladder	3%			3%	Uterine corpus
Non-Hodgkin	3%	lymphoma		2%	Liver & intrahepat
Kidney & renal pelvis	3%				bile duct
All other sites	25%			2%	Brain/ONS
				25%	All other sites

Site	1975-1977	1984-1986	1996-2004
All sites	50	54	66
Breast (female)	75	79	89
Colon	52	59	65
Leukemia	35	42	51
Lung and bronchus	13	13	16
Melanoma	82	87	92
Non-Hodgkin lymphoma	48	53	65
Ovary	37	40	46
Pancreas	3	3	5
Prostate	69	76	99
Rectum	49	57	67
Urinary bladder	74	78	81

Traditional epidemiology

Traditional epidemiology

E ----- D

Exposure

Disease

Tobacco




Lung Cancer



Molecular epidemiology

Molecular epidemiology



Lung cancer case control

Lung Cancer Case Control









EAGLE example

EAGLE example: molecular epidemiology approach

Epidemiology


'doneness module'




- What has molecular epidemiology contributed? 3 examples.....
- 1 HPV is the cause of 100% of cervical cancer
 - prevention is possible (vaccine)
 - 2 'Cutting down' on smoking is ineffective
 - biomarker studies show levels of carcinogens don't decline
- 3. GWAS studies (100 + conditions) based on biospecimen collections...

Integrative epidemiology

Integrative epidemiology



Integrative epidemiology



Consortia

Consortia (selected examples)

- BPC3 (Breast and Prostate Cancer and Hormone-Related Gene Variant Study)
- CADISP (Cervical Artery Dissections and Ischemic Stroke Patients)
- CARe (Candidate-gene Association REsource)
- CGASP (Consortium of Genetic Association of Smoking Related Phenotypes)
- CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology)
- CKDGen Consortium
- COGENT (COlorectal cancer GENeTics)
- DentalSCORE (Dental Strategies Concentrating on Risk Evaluation)
- DGI (Diabetes Genetics Initiative)
- DIAGRAM (Diabetes Genetics Replication And Metaanalysis Consortium)
- eMERGE (Electronic Medical Records & Genomics)
- ENGAGE (European Network of Genomic and Genetic Epidemiology)
- EUROCRAN (European Collaboration on Craniofacial Anomalies)
- GAPPS (Global Alliance to Prevent Prematurity and Stillbirth)
- GARNET (Genomics and Randomized Trials Network)
- GEFOS (Genetic Factors of Osteoporosis Consortium)
- GENEVA (GENe EnVironment Association studies)
- GIANT (Genome-wide Investigation of ANThropometric measures)

- Global BPGen Consortium
- Global Lipid Genetics Consortium
- ILCCO (International Lung Cancer Consortium)
- INTERLYMPH Consortium
- International Type 2 Diabetes Consortium
- ISGC (International Stroke Genetics Consortium)
- MAGIC (The Meta-Analyses of Glucose and Insulin-related traits Consortium)
- NEIGHBOR (National Eye Institute Glaucoma Human Genetics CollaBORation)
- NGFN (German National Genome Research Network)
- P3G Consortium (Public Population Project in Genomics)
- PAGE (Population Architecture using Genomics and Epidemiology)
- PREGENIA (Preterm Birth and Genetics International Alliances)
- SHARe (SNP Health Association Research)
- SpiroMeta Consortium
- SUNLIGHT Consortium (Study of Underlying Genetic Determinants of Vitamin D and Highly Related Traits)
- TAG (The Tobacco, Alcohol and Genetics Consortium)
- WTCCC (Wellcome Trust Case-Control Consortium)

4.2+ million subjects followed in cohorts

PhenX...approach to expand data collection and reduce misclassification



Home Project → Steering Committee → Working Groups → PhenX Toolkit → News →

PhenX Toolkit

PhenX High-Priority Measures are available now in the PhenX Toolkit at:

https://www.phenxtoolkit.org

The PhenX Toolkit is a web-based catalog of high priority measures for consideration and inclusion in genome-wide association studies (GWAS) and other large-scale genomic research efforts. Investigators may want to visit the Toolkit to review and select PhenX measures when designing a new study or expanding an ongoing study.

Exposure: gaps in understanding

- Contribution of environment to cancer
 - Universally estimated to be substantial
 - Clear success for selected risk factors/cancers
 - limited understanding of extrinsic environmental risks for many cancers: prostate, leukemia's, brain, sarcomas, pediatric, lung in nonsmokers, etc.
 - International variation poorly understood
 - Many exposures that are thought to be important- are difficult or impossible to access

EXPOSURE AREAS

Exposure areas with candidate emerging technologies:

Sleep Physical activity/inactivity Vital signs- heart rate Social factors Location **Smoking** Weather/climate Circadian variation

examples: Sleep Physical activity/inactivity Vital signs- heart rate Social factors Location **Smoking** Weather Circadian variation


SLEEP

Sleep

Sleep quantity
Sleep quality
Sleep interruptions
Stages of sleep
REM sleep
Wakefulness
Avg. time in bed



Technologies



Technologies very rapidly evolving

EXAMPLES:

Sleep

Physical activity/inactivity

Vital signs- heart rate Social factors

Location

Smoking

Weather

Circadian variation

Physical activity

Physical activity/inactivity

Type and quality of exercise

Timing of movement Periods of inactivity Calories

Steps

Climbing

Distance

Indices of fitness:

- Body fat
- Breathing rate
- Heart rate
- Pulse ox





Many Apps: RunKeeper, S Health, MyFitnessPal

Vital Signs

Vital signs

Heart rate
Heart rate variability
Arrhythmias
Max and min
Relation to diet/exercise

Examples:

- Polar line of 'watches'
- FitBit
- Adidas, Nike, etc.
- newer Apple, Samsung



examples:
Sleep
Physical activity/inactivity
Vital signs- heart rate
Social factors

Location
Smoking
Weather
Circadian variation


Social data

Social data

Data on social factors often absent from epidemiologic study designs Can quantitate:

contacts,
'friends',
indices of interaction,
relationships,
frequency of contact

Social networks



The Spread of Obesity in a large social network over 32 years. New Eng J Med 26jul, 2007, Christakis NA et al.

examples:
Sleep
Physical activity/inactivity
Vital signs- heart rate
Social factors

Location

Smoking
Weather
Circadian variation


Location

Local economic factors, SES Employment types/occupational exposures Zipcode Health care access Amount and sources of pollution Degree and type of urbanization Weather and climate (sun exposure/ozone) Local travel/time travelling/type of travel Characterize time and features of auto travel

examples: Sleep Physical activity/inactivity Vital signs- heart rate Social factors Location **Smoking** Weather Circadian variation

Help for Smokers


Help for smokers!!




examples: Sleep Physical activity/inactivity Vital signs- heart rate Social factors Location **Smoking** Weather/Climate Circadian variation

Climate and Cancer

Climate and Cancer





Specific extreme weather events
Pollution (air, water, land)
Impact on food/nutrition
Hydrology (water supply)
Dominant air masses
mP, cP, cA, mT

Sea level
Salinity of water
Biosphere
Sun exposure (albedo, cloud cover)
Insect vectors
Degree and type of vegetation
Climate zones (progression)

examples: Sleep Physical activity/inactivity Vital signs- heart rate Social factors Location **Smoking** Weather Circadian variation


Circadian variation

Circadian variation

Internal body time is related to: disease susceptibility chronotherapy


Internal body time determined by 2 blood samples

Also can be determined by activity/sleep/food cycles



Tracking daily activity

Tracking daily activity



Next step: 'virtual' cohort Sign up in diverse locations: hospital/healthy Regional biorepository with tissue access Link to pathology/medical records **Database** Consent, security, privacy protection Disease ascertainment Lifestyle, habits, hobbies, home, workplace Regular electronic follow-up